Αποτελέσματα Αναζήτησης
21 Απρ 2023 · Of the pathogenic Klebsiella species, K. pneumoniae is the most prevalent and clinically important. Infections with K. pneumoniae are usually hospital-acquired and occur primarily in patients with impaired host defenses.
- Keri K Hall, Md, Ms
Clinical features, diagnosis, and treatment of Klebsiella...
- Tsay Rw, SIU Lk, Fung Cp, Chang Fy. Characteristics of Bacteremia Between Community-Acquired and Nosocomial Klebsiella Pneumoniae Infection: Risk Factor for Mortality and The Impact of Capsular Serotypes as a Herald for Community-Acquired Infection. Arch Intern Med 2002; 162:1021
Klebsiella pneumoniae liver abscesses, which were all...
- Keri K Hall, Md, Ms
13 Ιουν 2020 · Treatment for pneumonia involves curing the infection and preventing complications. People who have community-acquired pneumonia usually can be treated at home with medication. Although most symptoms ease in a few days or weeks, the feeling of tiredness can persist for a month or more.
18 Αυγ 2022 · Recently, meropenem/vaborbactam was authorized by EMA for the treatment of complicated UTI, complicated intra-abdominal infections (cIAI), VAP, and also in adults with disease caused by Gram-negative aerobic bacteria.
Until very recently, the pipeline of new drugs for the treatment of multidrug-resistant gram-negative pathogens had been described as “dry”. However, a number of new drugs with in vitro activity against multidrug-resistant strains of K. pneumoniae are now in development.
20 Ιουλ 2023 · Objectives: Describe the pathophysiology of Klebsiella. Identify the most common cause of hospital-acquired pneumonia in the United States. Recall patients most likely to get Klebsiella pneumonia. Review the evaluation and treatment of patients with Klebsiella pneumonia and the interprofessional team's role in managing patients with this condition.
7 Ιουλ 2021 · Treatment with intravenous phage therapy targeting Klebsiella in an end-stage prosthetic knee joint infection resulted in sustained clinical improvement and decreased key inflammatory cytokines. Analysis of in vitro anti-biofilm activity of KpJH46Φ2 showed a trend toward reduction in biofilm biomass.
The aim of this review is to discuss the challenges in the management and treatment of patients with infections because of K. pneumoniae carbapenemase (KPC)-producing K. pneumoniae (KPC-KP) and provide an expert opinion. Table 1. Species distribution of Class A KPC. Modified by Miriagou and colleagues. 2. Open in a new tab.
